US Stock MarketDetailed Quotes

ALC Alcon

Watchlist
  • 91.470
  • -0.970-1.05%
Close Nov 6 16:00 ET
  • 91.470
  • 0.0000.00%
Post 20:01 ET
45.23BMarket Cap41.20P/E (TTM)

About Alcon Company

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Company Profile

SymbolALC
Company NameAlcon
Listing DateApr 9, 2019
Founded1945
CEOMr. David J. Endicott
MarketNYSE
Employees25315
Fiscal Year Ends12-31
AddressRoyce Bedward,Chemin de Blandonnet 8,Vernier
CityGeneva
ProvinceGeneve (Geneva)
CountrySwitzerland
Zip Code1214
Phone41-817-293-04-50

Company Executives

  • Name
  • Position
  • Salary
  • David J. Endicott
  • Director and Chief Executive Officer
  • 12.33M
  • Sue-Jean Lin
  • Senior Vice President, Chief Information and Transformation Officer
  • --
  • Timothy C. Stonesifer
  • Chief Financial Officer
  • --
  • Ian Bell
  • President, Global Business and Innovation
  • --
  • F. Michael Ball
  • Chairman of the Board
  • 1.17M
  • D. Keith Grossman
  • Vice Chairman of the Board
  • 361.69K
  • Rajkumar Narayanan
  • President, International
  • --
  • Leon Sergio Duplan Fraustro
  • President, North America
  • --
  • Karen J. May
  • Independent Director
  • 325.52K
  • Scott H. Maw
  • Independent Director
  • 333.87K
  • Thomas H. Glanzmann
  • Independent Director
  • 352.98K
  • Dr. Arthur Cummings, M.D.
  • Independent Director
  • 284.68K
  • Lynn Dorsey Bleil
  • Independent Director
  • 296.31K
  • Ines Poschel
  • Independent Director
  • 293.86K
  • Dieter Spalti, PhD
  • Independent Director
  • 236.83K
  • Dr. Raquel C. Bono, M.D.
  • Independent Director
  • 256.66K
  • Laurent Attias
  • Head, Corporate Development, Strategy, Business Development and Licensing and Mergers and Acquisitions
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data